Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Motor end-plate analysis to diagnose immune-mediated myasthenia gravis in seronegative patients.

Nagaoka A. et al, (2022), J Neurol Sci, 443

Inhibition of Maternal-to-Fetal Transfer of IgG Antibodies by FcRn Blockade in a Mouse Model of Arthrogryposis Multiplex Congenita.

Coutinho E. et al, (2021), Neurol Neuroimmunol Neuroinflamm, 8

Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis.

Pollak TA. et al, (2021), Mol Psychiatry, 26, 2590 - 2604

Using AChR antibody titres to predict treatment responses in myasthenia gravis.

Vincent A., (2021), J Neurol Neurosurg Psychiatry

Neuronal surface antibodies are common in children with narcolepsy and active movement disorders.

Giannoccaro MP. et al, (2020), J Neurol Neurosurg Psychiatry

Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs.

Cetin H. et al, (2020), J Neurol Neurosurg Psychiatry

SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody.

Huda S. et al, (2020), Neurol Neuroimmunol Neuroinflamm, 7

Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia.

Vincent A. et al, (2018), JAMA Neurol, 75, 1519 - 1527

Investigation of neuronal auto-antibodies in children diagnosed with epileptic encephalopathy of unknown cause.

Tekturk P. et al, (2018), Brain Dev, 40, 909 - 917

Plasma cell depletion with bortezomib in the treatment of refractory N-methyl-d-aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment.

Keddie S. et al, (2018), Eur J Neurol, 25, 1384 - 1388

NMDA-receptor antibodies alter cortical microcircuit dynamics.

Rosch RE. et al, (2018), Proc Natl Acad Sci U S A, 115, E9916 - E9925

Antiglycine receptor antibody related disease: a case series and literature review.

Swayne A. et al, (2018), Eur J Neurol, 25, 1290 - 1298

Passive Transfer of Human CASPR2 Antibodies into Mice Causes Behavioral and Neuropathological Changes

Giannoccaro MP. et al, (2018), ANNALS OF NEUROLOGY, 84, S137 - S137

SHP2 INHIBITION BY NSC-87877 RECOVERS THE PATHOGENIC IN VITRO EFFECTS OF MUSK-MG ANTIBODY SUBCLASSES

Cao M. et al, (2018), MUSCLE & NERVE, 58, S15 - S16

Glutamate receptor δ2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome.

Berridge G. et al, (2018), Neurology, 91, e714 - e723

A passive transfer animal model of CASPR2 antibodies

Giannoccaro MP. et al, (2018), EUROPEAN JOURNAL OF NEUROLOGY, 25, 674 - 674

Brain-relevant antibodies in first-episode psychosis: a matched case-control study.

Gaughran F. et al, (2018), Psychol Med, 48, 1257 - 1263

Pathogenic Mechanisms and Clinical Correlations in Autoimmune Myasthenic Syndromes.

Cetin H. and Vincent A., (2018), Semin Neurol, 38, 344 - 354

Clinical presentation and prognosis in MOG-antibody disease: a UK study (vol 140, pg 12, 2017)

Jurynczyk M. et al, (2018), BRAIN, 141

Endocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody.

Hacohen Y. et al, (2018), Mult Scler, 24, 679 - 684

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?